Surgery, Gastroenterology and Oncology
Vol. 23, No. 3, Jun 2018
Predictors of Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasms and Applicability of Current Guidelines
Vítor Bruno Santos Devezas, Tiago de Queirós Bouça Ribeirinho Machado, Hugo Miguel Teixeira Ferraz Santos-Sousa, Manuel António Azevedo Oliveira, Luís Afonso Meireles Maio Graça, José Eduardo Fernandes Costa Maia
ORIGINAL PAPER, Jun 2018
Article DOI: 10.21614/sgo-23-3-174
Introduction: Pancreatic intraductal papillary mucinous neoplasms (IPMN) are recognized as pre-malignant lesions, corresponding to less than 3% of all pancreatic exocrine neoplasms. The study objectives were: to evaluate the surgical results of our institution, to identify factors predicting malignancy in IPMN and to assess the validity of recently introduced IPMN guidelines in our population.

Methods: A single center, retrospective study in patients submitted to surgical resection for IPMN was conducted, between 1 2008-6 2016, to identify predictive factors for malignancy, and to evaluate the surgical results.

Results: Thirty-nine patients were submitted to a surgical resection. The median age was 68 years (61.5% females). Adenocarcinoma and high-grade dysplasia were present, in 7 and 4 patients, respectively. A significant association was identified with the phenotype and the degree of atypia (p = 0.001), and duct origin and degree of atypia (p = 0.026). Malignant transformation was associated with intestinal or pancreatic-biliary subtypes.

Discussion and Conclusions: Applying the European guidelines, all adenocarcinoma would have undergone surgical resection, but 1 with high-grade dysplasia would not be resected. If we applied the American guidelines, 1 patient with adenocarcinoma and 3 with high-grade dysplasia wouldn't be submitted to resection. The decision in patients with these lesions requires multidisciplinary teams and a tailored based approach.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 3065


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.